ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 130 filers reported holding ENANTA PHARMACEUTICALS INC in Q2 2016. The put-call ratio across all filers is 0.92 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $127 | -78.8% | 11,404 | -59.3% | 0.00% | -100.0% |
| Q2 2023 | $600 | -49.1% | 28,009 | -4.0% | 0.00% | -66.7% |
| Q1 2023 | $1,178 | -16.4% | 29,185 | -3.6% | 0.00% | -25.0% |
| Q4 2022 | $1,409 | -99.9% | 30,264 | +28.4% | 0.00% | +33.3% |
| Q3 2022 | $1,221,000 | +43.1% | 23,573 | +30.7% | 0.00% | +50.0% |
| Q2 2022 | $853,000 | -26.2% | 18,034 | +14.0% | 0.00% | 0.0% |
| Q1 2022 | $1,156,000 | -2.2% | 15,823 | +0.1% | 0.00% | 0.0% |
| Q4 2021 | $1,182,000 | +31.9% | 15,806 | +0.6% | 0.00% | 0.0% |
| Q3 2021 | $896,000 | +29.5% | 15,714 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $692,000 | -10.0% | 15,714 | +0.2% | 0.00% | 0.0% |
| Q1 2021 | $769,000 | +5.5% | 15,681 | -9.4% | 0.00% | +100.0% |
| Q4 2020 | $729,000 | -19.4% | 17,317 | -12.3% | 0.00% | -50.0% |
| Q3 2020 | $904,000 | -10.3% | 19,754 | -1.8% | 0.00% | 0.0% |
| Q2 2020 | $1,008,000 | -3.6% | 20,119 | -1.4% | 0.00% | -33.3% |
| Q1 2020 | $1,046,000 | -12.4% | 20,398 | +4.7% | 0.00% | 0.0% |
| Q4 2019 | $1,194,000 | -32.4% | 19,487 | -7.0% | 0.00% | -25.0% |
| Q2 2019 | $1,766,000 | -11.2% | 20,952 | +0.6% | 0.00% | -20.0% |
| Q1 2019 | $1,989,000 | +51.4% | 20,828 | +3.6% | 0.01% | +25.0% |
| Q4 2018 | $1,314,000 | -16.6% | 20,109 | +9.0% | 0.00% | 0.0% |
| Q3 2018 | $1,575,000 | -26.3% | 18,452 | 0.0% | 0.00% | -20.0% |
| Q2 2018 | $2,138,000 | +42.0% | 18,452 | -0.9% | 0.01% | +25.0% |
| Q1 2018 | $1,506,000 | +29.5% | 18,617 | -6.1% | 0.00% | +33.3% |
| Q4 2017 | $1,163,000 | +16.0% | 19,835 | -9.0% | 0.00% | +50.0% |
| Q3 2017 | $1,003,000 | +48.4% | 21,791 | +16.0% | 0.00% | 0.0% |
| Q2 2017 | $676,000 | +16.8% | 18,785 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $579,000 | +0.5% | 18,785 | +9.3% | 0.00% | 0.0% |
| Q4 2016 | $576,000 | -37.0% | 17,185 | -50.0% | 0.00% | +100.0% |
| Q3 2016 | $914,000 | +157.5% | 34,370 | +113.3% | 0.00% | 0.0% |
| Q2 2016 | $355,000 | – | 16,117 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 862,848 | $42,556,000 | 14.73% |
| Fairmount Funds Management LLC | 171,147 | $8,441,000 | 3.56% |
| ARMISTICE CAPITAL, LLC | 1,648,000 | $81,279,000 | 1.87% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,995,000 | $98,393,000 | 0.49% |
| Jackson Creek Investment Advisors LLC | 21,409 | $1,056,000 | 0.37% |
| Hennion & Walsh Asset Management, Inc. | 113,940 | $5,620,000 | 0.34% |
| Virtus ETF Advisers LLC | 14,721 | $726,000 | 0.31% |
| Granahan Investment Management | 193,416 | $9,539,000 | 0.20% |
| Yorktown Management & Research Co Inc | 4,500 | $222,000 | 0.18% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 242,257 | $11,948,000 | 0.09% |